Public Sector Pension Investment Board Has $10.39 Million Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Public Sector Pension Investment Board grew its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 15.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 486,988 shares of the biopharmaceutical company’s stock after purchasing an additional 64,736 shares during the period. Public Sector Pension Investment Board owned about 0.29% of ACADIA Pharmaceuticals worth $10,392,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Geneos Wealth Management Inc. boosted its position in ACADIA Pharmaceuticals by 113.0% during the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 756 shares during the period. Smartleaf Asset Management LLC increased its position in ACADIA Pharmaceuticals by 107.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 885 shares during the period. USA Financial Formulas bought a new position in shares of ACADIA Pharmaceuticals during the third quarter valued at $41,000. GAMMA Investing LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 25.8% during the third quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 690 shares during the period. Finally, State of Wyoming acquired a new position in shares of ACADIA Pharmaceuticals during the third quarter worth $177,000. 96.71% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the sale, the executive vice president owned 7,609 shares of the company’s stock, valued at $177,898.42. This trade represents a 47.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock opened at $22.03 on Tuesday. ACADIA Pharmaceuticals Inc. has a one year low of $13.40 and a one year high of $28.35. The stock’s 50-day moving average is $26.01 and its 200 day moving average is $24.45. The firm has a market cap of $3.73 billion, a price-to-earnings ratio of 14.21, a PEG ratio of 7.73 and a beta of 0.66.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on ACAD shares. Oppenheimer restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. JPMorgan Chase & Co. decreased their price target on ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a research note on Monday, November 17th. Stifel Nicolaus set a $37.00 price objective on ACADIA Pharmaceuticals in a research report on Tuesday, December 16th. Wall Street Zen lowered ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Finally, Mizuho increased their target price on shares of ACADIA Pharmaceuticals from $24.00 to $29.00 and gave the company a “neutral” rating in a research report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.30.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.